Presentation is loading. Please wait.

Presentation is loading. Please wait.

LYME DISEASE n Epidemiology n Clinical Manifestations n Differential Diagnosis n Diagnosis n Treatment n Prevention.

Similar presentations


Presentation on theme: "LYME DISEASE n Epidemiology n Clinical Manifestations n Differential Diagnosis n Diagnosis n Treatment n Prevention."— Presentation transcript:

1 LYME DISEASE n Epidemiology n Clinical Manifestations n Differential Diagnosis n Diagnosis n Treatment n Prevention

2 EPIDEMIOLOGY n Caused by spirochete Borrelia burgdorferi n Transmitted by Ixodes ticks n Nymph-stage ticks feed on humans May through July - transmit spirochete n Endemic areas –Northeastern coastal states –Wisconsin & Minnesota –Coast of Oregon & northern California

3 Ixodes scapularis ticks

4 Larva, nymph, and adult female and male Ixodes dammini ticks

5 EPIDEMIOLOGY (cont) n >  of dear ticks carry spirochete n Rising frequency attributed to enlarging deer population & concurrent suburbanization n High risk areas - wooded or brushy, unkempt grassy areas & fringe of these areas n Lower risk on lawns that are mowed

6 MAJOR RISK FACTORS n Geographical –Northeast, north-central (Wisconsin, Minnesota) coastal regions of California & Oregon n Occupational –Landscaper, forester, outdoor n Recreational –hiking, camping, fishing, hunting

7 CLINICAL MANIFESTATIONS n Stage 1 - Acute, localized disease n Stage 2 - Subacute, disseminated disease n Stage 3 - Chronic or late persistent infection

8 ACUTE INFECTION n Tick must have been feeding for at least hrs n Erythema migrans develops 1 to 4 weeks after bite n Without treatment rash clears within 3 to 4 weeks n About 50% of pts will also c/o flulike illness - fever, H/A, chills, myalgia

9 DISSEMINATED DISEASE n May develop in wks to mos in untreated pts n Symptoms usually involve skin, CNS, musculoskeletal system, & cardiac n Dermatological manifestations –new skin lesions, smaller and less migratory than initial –Erythema and urticaria have been noted

10 DISSEMINATED (cont) n Neurologic complications n Occurs wks to mos later in about 15% to 20% of untreated n Symptoms –Lyme meningitis –mild encephalopathy –unilateral or bilateral Bell’s palsy –peripheral neuritis

11 Left facial palsy (Bell's palsy) in early Lyme disease

12 DISSEMINATED (cont) n Musculoskeletal symptoms n Symptoms evolve into frank arthritis in up to 60% of untreated pts n Onset averages 6 mos from initial infection n Symptoms –migratory joint, muscle, & tendon pain –knee most common site –no more than 3 joints involved during course –lasts several days to few weeks then joint returns to normal

13 DISSEMINATED (cont) n Cardiac involvement n Noted in about 5% to 10% beginning several wks after infection n Transient heart block may be consequence n Range from asymptomatic to first- degree heart block to complete n Cardiac phase lasts from 3 to 6 wks

14 CHRONIC - LATE PERSISTENT n Follows latent period of several mos to a yr after initial infection n 60% to 80% will have musculoskeletal complaints n Most common; arthritis of knee - may also occur in ankle, elbow, hip, shoulder

15 CHRONIC (cont) n Neurologic impairment –distal paresthesias –radicular pain –memory loss –fatigue

16 NATURAL HISTORY n Without treatment will see disseminated disease in about 80% of pts n Oligoarthritis - 60% to 80% n Chronic neurologic & persistent joint symptoms - 5% to 10%

17 Clinical stages of Lyme disease

18 CONCURRENT INFECTIONS n Human babesiosis –fever, chills, sweats, arthralgias, headache, lassitude –pts with both appear to have more severe Lyme disease n Ehrlichiosis –described as “rashless Lyme disease” –high fever & chills & may become prostrate in day or two

19 DIFFERENTIAL DIAGNOSIS n Acute & early disseminated stages –Rocky Mountain spotted fever –human babiosis –summertime viral illnesses –viral encephalitis –bacterial meningitis

20 DIFFERENTIAL (cont) n Late disseminated & chronic stages –gout –pseudogout –Reiter’s syndrome, psoriatic arthritis, ankylosing spondylitis –rheumatoid arthritis –depression –fibromyalgia –chronic fatigue syndrome

21 DIAGNOSIS n Clues to early disease –EPIDEMIOLOGIC n travel or residence in endemic area within past month n h/o tick bite (especially within past 2 weeks) n late spring or early summer (June, July, August)

22 EARLY DISEASE (cont) –RASH n expanding lesion over days (rather than hours or stable over months) n central clearing or target appearance n minimal pruritis or tenderness n central papular erythema, pigmentation, or scaling at sit of tick bite n lack of scaling n location at sites unusual for bacterial cellulitis (usually axillae, popliteal fossae, groin, waist

23 Erythema (chronicum) migrans

24 Single erythema migrans

25 EARLY DISEASE (cont) –ASSOCIATED SYMPTOMS n fatigue n myalgia/arthralgia n headache n fever and/or chills n stiff neck n respiratory & GI complaints are infrequent

26 EARLY DISEASE (cont) –PHYSICAL EXAM n Regional lymphadenopathy n Multiple erythema migrans lesion n Fever

27 DISSEMINATED DISEASE n Clinical presentation can make diagnosis –epidemiological inquiry –review of key historic features –physical findings –serum for antibody testing –spinal tap

28 LATE DISEASE n Careful attention to musculoskeletal & neurologic symptoms n Differentiating Lyme from fibromyalgia & CFS –oligoarticular musculoskeletal complaints that include signs of joint inflammation –limited & specific neuro deficits –abnormalities of CFS –absence of disturbed sleep, chronic H/A, depression, tender points

29 ANTIBODY TESTING n Testing with ELISA is not required to confirm diagnosis n Pts with objective clinical signs have high pretest probability of disease n Tests are not sensitive in very early disease n Should not use is pt without subjective symptoms of Lyme

30 TESTING(cont) n A + test in person with low probability of disease risks false + rather than true + n Test when pts fall between these two extremes –pt with lesion or symptoms without known endemic exposure (new area) –pretest probability now has high sensitivity & specificity

31 TESTING (cont) n For a positive or equivocal ELISA or IFA CDC recommends Western blot n Testing cannot determine cure as pt remains antibody + n PCR is being developed - still considered investigational

32 TREATMENT n Early Lyme disease –doxycycline, 100 mg BID for 21 to 18 days –amoxicillin, 500 mg TID for 21 to 28 days –cefuroxime, 500 mg BID for 21 days

33 PREVENTION n Wear light-colored clothes - easier to spot tick n Wear long pants, long sleeves n Use tick repellent, such as permethrin, on clothes n Use DEET on skin n Check for ticks after being outside n Remove ticks immediately by head

34 VACCINATION NO LONGER AVAILABLE

35 WEST NILE VIRUS n Summer first detected in NYC & Western hemisphere n 59 hospitalized - epicenter Queens - 7 died n Summer epicenter Staten Island - 19 hospitalized - 2 died n For states, 3737 confirmed cases, 214 deaths

36 INFECTIOUS AGENT n Member of family Filaviviridae n Belongs to Japanese encephalitis complex n Before 1999 outbreaks seen only in Africa, Asia, Middle East, rarely Europe n Reservoir & Mode of transmission –wild birds primary reservoir & Culex spp. major mosquito vector

37 INCUBATION PERIOD/SYMPTOMS n Incubation usually 6 days (range 3-15) n Symptoms –milder: fever, headache, myalgias, arthralgias, lymphadenopathy, maculopapular or roseolar rash affecting trunk & extremities –occasionally reported: pancreatitis, hepatitis, myocarditis –CNS involvement rare & usually in elderly

38 TREATMENT n No known effective antiviral therapy or vaccine n Intensive supportive in more severe cases

39 DIFFERENTIAL DIAGNOSIS n Enteroviruses n Herpes simplex virus n Varicella

40 TESTING n Lab conformation based on following criteria: –isolating West Nile virus from or demonstrating viral antigen or genomic sequences in tissue, blood, CSF, or other body fluid –demonstrating IgM antibody to West Nile virus in CSF by ELISA –demonstrating 4-fold serial change in plaque reduction neutralization test (PRNT) antibody to West Nile virus in paired, acute & convalescent serum samples –demonstrating both West Nile virus-specific IgM & IgG antibody in single serum specimen using ELISA & PRNT

41 Must report suspected cases of West Nile to the NYC Department of Health During business hours call Communicable Disease Program (212) At all other times call Poison Control Center - (212)

42 INFECTIOUS MONONUCLEOSIS n Infectious mononucleosis - designates the clinical syndrome of prolonged fever, pharyngitis, lymphadenopathy n Epstein-Barr virus-associated infectious mononucleosis (EBV-IM) n non Epstein-Barr virus-associated infectious mononucleosis (non-EBV-IM) –approximately 10-20% have

43 EPIDEMIOLOGY n >90% of adults have serologic evidence of prior EBV infection n Mean age of infection varies n In US 50% of 5-year-old children & % of first-year college students have evidence of prior infection n Infection in children most prevalent amongst lower socioeconomic n peak rate of EBV-IM

44 n Chance of acute EBV infection leading to IM  with age n Good sanitation & uncrowded living conditions  risk of EBV-IM

45 OTHER CAUSES OF IM n CMV n Human herpesvirus 6 n HIV n Adenovirus n Toxo n Corynebacterium diptheriae n Hep A n Rubella n Coxiella burnetii

46 CLINICAL MANIFESTIONS n Classic triad - fever, pharyngitis, lymphadenopathy n Prodrome- malaise, anorexia, fatigue, headache, fever n Symptoms usually peak 7 days after onset &  over next 1-3 wks n Splenic enlargement %

47 n Less common clinical features –upper airway compromise –abdominal pain –rash (ampicillin  risk of) –hepatomegaly –jaundice –eyelid edema

48 DIAGNOSTIC TESTING n Serologic test for heterophil antibodies n Percentage with antibodies higher > 4yrs old n % of persons who are + at 1 week varies with test (1 study - 69% + at 1 wk; 80% + by 3 wks) n False +s rare

49 n If heterophil antibody continues neg & still suspect; –serum for viral capsis antigen (VCA) IgG & IgM & for EBV nuclear antigen (EBNA) IgG –VCA antibodies + in many at onset

50 LABORATORY ABNORMALITIES n Total leukocyte count  n usually > 50% of total leukocytes consist of lymphocytes n possible mild thrombocytopenia n  LFTs fold n abnormalities on UA

51 IM IN OLDER ADULTS n 3-10% of persons >40 are susceptible n Presenting S & S different n Fever present but few have pharyngitis & lymphadenopathy n Jaundice in >20% n R/O; hepatobiliary disease, neoplasms, collagen vascular diseases, bacterial infections

52 MANAGEMENT n Supportive n NSAIDs or tylenol - no ASA n Bedrest during febrile stage n If have splenomegaly avoid vigorous activity for 3-4 wks n No evidence that steroids or antivirals are of benefit

53 CHRONIC FATIGUE SYNDROME n Has been called: chronic EBV syndrome, postviral fatigue syndrome, “yuppie flu” n 1988 CDC convened researchers & clinicians to define & classify CFS n 1994 international group proposed guidelines for CFS n CDC reported prevalence of 4-11 cases/100,000 population n In US most cases occur in young to middle- aged white women

54 ETIOLOGY n No cause identified n Postulated –infective –neuromuscular –immunologic –neurologic –psychiatric

55 DIAGNOSTIC CRITERIA (PER CDC) Fatigue criteria n Must not be lifelong n Must be persistent, relapsing & unexplained n Must not be result of ongoing exertion & cannot be relieved by rest

56 Symptom Criteria n Sore throat n Short-term memory or concentration impairment n Tender cervical or axillary lymph nodes n Headaches of a new type, pattern, or severity n Unrefreshing sleep n Postexertional malaise lasting > 24 hrs n Multijoint pain without joint swelling or inflammation n Muscle pain

57 Exclusion Criteria n Past or current diagnosis of major depression with psychotic or melancholic features, bipolar disorder, schizophrenia, delusional disorders, dementia, bulimia nervosa, anorexia nervosa n Active medical conditions n Previously diagnosed conditions with unclear resolution (malignancies, hepatitis B or C) n Alcohol or substance abuse within 2 yrs of onset of fatigue n Severe obesity (BMI  45)

58 n Detailed medical history n Complete physical n Labs –CBC –ESR –TSH –UA –Serum chem for electrolytes, BUN, cr, glucose, calcium, phosphorus, alk phos, total protein, albumen, globulin, LFTs

59 MANAGEMENT Goal: Restore pts occupational & social functioning & prevent further disability. n Guidelines –Establish diagnosis –Prevent further disability –If indicated, start medication ASAP –Warn about unproven therapies –Initiate psychological intervention

60 PHARMACOTHERAPY n Antivirals n Immunomodulators n Psychotropic agents n Pain medications n Antiallergy medications n Acetylcholinesterase inhibitors n Agents used in alternative medicine

61 NONPHARMACOLOGIC TREATMENT n Exercise n Cognitive behavior therapy n Self-help groups n Work as therapeutic modality

62 DIFFERENTIAL n Fibromyalgia n Endocrine n Chronic viral infections n Malignancy n Sleep disorders causing fatigue n Connective tissue diseases n Body weight changes n Side effects of medications n Other illnesses

63 PSYCHIATRIC CONDITIONS EXCLUDING CFS DIAGNOSIS n Major depressive episodes n Anxiety disorders n Delusional disorders n Bipolar disorder n Schizophrenia n Eating disorders n Dementias n Sleep disorders n Substance use disorders

64 HERPES ZOSTER n Represents reactivation of varicell- zoster virus n Latently resides in a dorsal root or cranial nervie ganglia n Multiple erythematous plaques with clustered vesicles n Vesicles begin to dry & crust in 7-10 days, clear within 2-3 wks, new may continue to appear for up to 1 wk

65 COMMON DISTRIBUTION n Thoracic dermatome 50% n Cervical dermatome20% n Trigeminal dermatome15% n Lumbosacral dermatome10%

66 PRESENTATION/DIAGNOSIS n Prodrome n Vesicular rash n Diagnosis - presentation

67 Herpes zoster

68 Acute herpes zoster ophthalmicus

69 POTENTIAL COMPLICATIONS n Trigeminal dermatome –may affect second branch associated with involvement of eye n keratitis, uveitis, secondary glaucoma, iridocyclitis n Ramsay-Hunt syndrome –affects facial & auditory nerves –facial palsy with cutaneous zoster of external ear or TM, with associated tinnitus, vertigo, &/or hearing loss

70 TREATMENT n Early treatment –within hrs n Acyclovir (Zovirax) –800mg 3x/day n Valacyclovir (Valtrex) –1,000mg 3x/day n Famciclovir (Famvir) –500mg 3x/day

71 POSTHERPETIC NEURALGIA n Famvir and Valtrex  incidence n Capsaicin cream (Zostrix 0.025% & Zostrix HP 0.075%) 4x/day n Amitriptyline n Gabapentin n Often remits spontaneously after 6 months n Pain referral


Download ppt "LYME DISEASE n Epidemiology n Clinical Manifestations n Differential Diagnosis n Diagnosis n Treatment n Prevention."

Similar presentations


Ads by Google